Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, 7SL, cytoplasmic 22, pseudogene" (RN7SL22P) is classified as a **pseudogene** of the non-coding RNA known as 7SL RNA, which is a component of the signal recognition particle (SRP) complex in its canonical form (RN7SL1)[9][1]. Pseudogenes are genomic sequences similar to known genes but are typically non-functional and do not code for functional products, usually due to disabling mutations or truncation[6][8]. RN7SL22P is not known to be expressed or functional, and there is no evidence establishing it as a therapeutic target, biomarker, or direct contributor to disease. Like other pseudogenes, it might retain some capacity for regulatory functions, such as generating non-coding RNAs involved in gene regulation (for example, as microRNA decoys or sources of endogenous siRNAs), but no such function has been specifically described for RN7SL22P to date[4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, 7SL, cytoplasmic 22, pseudogene (RN7SL22P).